The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.

"The CIRM grant will enable ReviR Therapeutics to further develop their preclinical candidate through rigorous preclinical studies and into clinical trials, with an initial goal to ensure that the ...

ProFound Therapeutics will use its proteomic technology and Quotient Therapeutics its genomics platform to uncover respiratory and liver disease treatments.

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

The firms will use the funds to integrate FYR's liquid biopsy platform in NuvOx's Phase II trial evaluating the oxygen therapeutic NanO₂ as a radiosensitizer.

The Shanghai-based firm will evaluate the safety of the therapy and its efficacy in reducing urinary oxalate levels and improving renal outcomes.

The agency considered clinical trial data showing Redemplo can significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome versus placebo.